Cargando…
Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome
BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex condition with high risk for dyslipidemia, dysglycemia, venous thromboembolism, cardiovascular disease and metabolic syndrome. Because the combined oral contraceptive (COC) use has also been associated with impaired fasting glucose, insulin r...
Autor principal: | de Medeiros, Sebastião Freitas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721684/ https://www.ncbi.nlm.nih.gov/pubmed/29216881 http://dx.doi.org/10.1186/s12958-017-0313-y |
Ejemplares similares
-
Combined Oral Contraceptive Effects on Low-Grade Chronic Inflammatory Mediators in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
por: de Medeiros, Sebastião Freitas, et al.
Publicado: (2018) -
Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits
por: de Melo, Anderson Sanches, et al.
Publicado: (2017) -
Influence of combined oral contraceptives on polycystic ovarian morphology-related parameters in Korean women with polycystic ovary syndrome
por: Park, Chan-Hong, et al.
Publicado: (2020) -
Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women
por: de Medeiros, Sebastião Freitas, et al.
Publicado: (2017) -
The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study
por: de Medeiros, Sebastiao Freitas, et al.
Publicado: (2018)